Promimic AB
Promimic AB (publ) manufactures, markets, and sells biomaterials for improved osseointegration for orthopedic and dental implants markets. It offers HAnano surface technology that combines various properties that are known to improve osseointegration into one unique surface modification. The company was incorporated in 2004 and is based in Mölndal, Sweden.
Promimic AB (PRO) - Net Assets
Latest net assets as of December 2025: Skr59.11 Million SEK
Based on the latest financial reports, Promimic AB (PRO) has net assets worth Skr59.11 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr75.71 Million) and total liabilities (Skr16.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr59.11 Million |
| % of Total Assets | 78.07% |
| Annual Growth Rate | 19.26% |
| 5-Year Change | 161.91% |
| 10-Year Change | N/A |
| Growth Volatility | 94.51 |
Promimic AB - Net Assets Trend (2018–2025)
This chart illustrates how Promimic AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Promimic AB (2018–2025)
The table below shows the annual net assets of Promimic AB from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr59.11 Million | -15.46% |
| 2024-12-31 | Skr69.91 Million | -8.87% |
| 2023-12-31 | Skr76.72 Million | -5.66% |
| 2022-12-31 | Skr81.32 Million | +260.32% |
| 2021-12-31 | Skr22.57 Million | -39.46% |
| 2020-12-31 | Skr37.27 Million | +43.71% |
| 2019-12-31 | Skr25.94 Million | +50.61% |
| 2018-12-31 | Skr17.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Promimic AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8442613000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.89 Million | 3.20% |
| Other Components | Skr202.87 Million | 343.22% |
| Total Equity | Skr59.11 Million | 100.00% |
Promimic AB Competitors by Market Cap
The table below lists competitors of Promimic AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Havila Shipping ASA
OL:HAVI
|
$8.40 Million |
|
BioMark Diagnostics Inc
PINK:BMKDF
|
$8.41 Million |
|
Taiwan Thick-Film Ind
TWO:6246
|
$8.41 Million |
|
Gauzy Ltd. Ordinary Shares
NASDAQ:GAUZ
|
$8.41 Million |
|
Shengfeng Development Limited Class A Ordinary Shares
NASDAQ:SFWL
|
$8.40 Million |
|
Garuda Maintenance Facility AeroAsia Tbk PT
JK:GMFI
|
$8.40 Million |
|
Paringa Resources Limited
PINK:PNGZF
|
$8.40 Million |
|
Bicycle Therapeutics plc
F:50BA
|
$8.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Promimic AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 69,914,000 to 59,107,000, a change of -10,807,000 (-15.5%).
- Net loss of 8,800,000 reduced equity.
- Other comprehensive income decreased equity by 487,999.
- Other factors decreased equity by 1,519,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-8.80 Million | -14.89% |
| Other Comprehensive Income | Skr-488.00K | -0.83% |
| Other Changes | Skr-1.52 Million | -2.57% |
| Total Change | Skr- | -15.46% |
Book Value vs Market Value Analysis
This analysis compares Promimic AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.77x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.91x to 3.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Skr0.99 | Skr11.80 | x |
| 2019-12-31 | Skr1.49 | Skr11.80 | x |
| 2020-12-31 | Skr2.16 | Skr11.80 | x |
| 2021-12-31 | Skr1.82 | Skr11.80 | x |
| 2022-12-31 | Skr5.15 | Skr11.80 | x |
| 2023-12-31 | Skr4.15 | Skr11.80 | x |
| 2024-12-31 | Skr3.72 | Skr11.80 | x |
| 2025-12-31 | Skr3.13 | Skr11.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Promimic AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19.82%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.28x
- Recent ROE (-14.89%) is above the historical average (-37.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -87.02% | -384.36% | 0.16x | 1.42x | Skr-16.71 Million |
| 2019 | -43.55% | -196.67% | 0.18x | 1.26x | Skr-13.89 Million |
| 2020 | -35.70% | -240.83% | 0.13x | 1.19x | Skr-17.18 Million |
| 2021 | -67.29% | -188.26% | 0.25x | 1.43x | Skr-17.44 Million |
| 2022 | -19.54% | -97.98% | 0.17x | 1.14x | Skr-24.02 Million |
| 2023 | -12.02% | -24.88% | 0.40x | 1.21x | Skr-16.89 Million |
| 2024 | -17.95% | -28.54% | 0.50x | 1.26x | Skr-19.54 Million |
| 2025 | -14.89% | -19.82% | 0.59x | 1.28x | Skr-14.71 Million |
Industry Comparison
This section compares Promimic AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $75,200,026
- Average return on equity (ROE) among peers: -74.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Promimic AB (PRO) | Skr59.11 Million | -87.02% | 0.28x | $8.40 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |